FXR activation prevents liver injury induced by Tripterygium wilfordii preparations

References

• Allen, K., Jaeschke, H., and Copple, B.L., 2011. Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. The American journal of pathology, 178 (1), 175–186.
   PubMed Web of Science ®Google Scholar
• An, P., et al., 2020. A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction. Liver international : official journal of the international association for the study of the liver, 40 (7), 1655–1669.
   PubMed Web of Science ®Google Scholar
• Armstrong, L.E. and Guo, G.L., 2017. Role of FXR in liver inflammation during nonalcoholic steatohepatitis. Current pharmacology reports, 3 (2), 92–100.
   PubMedGoogle Scholar
• Bao, J. and Dai, S.M., 2011. A Chinese herb Tripterygium wilfordii Hook F in the treatment of rheumatoid arthritis: mechanism, efficacy, and safety. Rheumatology international, 31 (9), 1123–1129.
   PubMed Web of Science ®Google Scholar
• Cao, L.J., et al., 2015. Progress on mechanism of Tripterygium wilfordii-induced liver injury and detoxification mechanism of licorice. Zhongguo Zhong Yao za Zhi = Zhongguo Zhongyao Zazhi = China journal of Chinese materia medica, 40 (13), 2537–2541.
   PubMedGoogle Scholar
• Dai, M., et al., 2020. Therapeutic action against chronic cholestatic liver injury by low-dose fenofibrate involves anti-chemotaxis via JNK-AP1-CCL2/CXCL2 signaling. Pharmacological reports : PR, 72 (4), 935–944.
   PubMed Web of Science ®Google Scholar
• Dai, M., et al., 2017. Inhibition of JNK signalling mediates PPARα-dependent protection against intrahepatic cholestasis by fenofibrate. British journal of pharmacology, 174 (18), 3000–3017.
   PubMed Web of Science ®Google Scholar
• Di Ciaula, A., et al., 2017. Bile acid physiology. Annals of hepatology, 16, s4–s14.
   PubMed Web of Science ®Google Scholar
• Ding, W., et al., 2019. Obeticholic acid differentially regulates hepatic injury and inflammation at different stages of d-galactosamine/lipopolysaccharide-evoked acute liver failure. European journal of pharmacology, 850, 150–157.
   PubMed Web of Science ®Google Scholar
• Fan, Y.Y., et al., 2019. Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3. International immunopharmacology, 77, 105911.
   PubMed Web of Science ®Google Scholar
• Forman, B.M., et al., 1995. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell, 81 (5), 687–693.
   PubMed Web of Science ®Google Scholar
• Gai, Z., et al., 2020. Obeticholic acid ameliorates valproic acid-induced hepatic steatosis and oxidative stress. Molecular pharmacology, 97 (5), 314–323.
   PubMed Web of Science ®Google Scholar
• Gao, X., et al., 2018. Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro. Toxicology and applied pharmacology, 348, 105–116.
   PubMed Web of Science ®Google Scholar
• Grek, A. and Arasi, L., 2016. Acute liver failure. AACN advanced critical care, 27 (4), 420–429.
   PubMed Web of Science ®Google Scholar
• Gupta, S., et al., 2001. Down-regulation of cholesterol 7alpha-hydroxylase (CYP7A1) gene expression by bile acids in primary rat hepatocytes is mediated by the c-Jun N-terminal kinase pathway. The journal of biological chemistry, 276 (19), 15816–15822.
   PubMed Web of Science ®Google Scholar
• Higuchi, H., et al., 2004. Bile acids up-regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Sp1. The journal of biological chemistry, 279 (1), 51–60.
   PubMed Web of Science ®Google Scholar
• Hofmann, A.F., 1999. The continuing importance of bile acids in liver and intestinal disease. Archives of internal medicine, 159 (22), 2647–2658.
   PubMed Web of Science ®Google Scholar
• Huang, J.F., et al., 2020. Gut microbiota protects from triptolide-induced hepatotoxicity: key role of propionate and its downstream signalling events. Pharmacological research, 155, 104752.
   PubMed Web of Science ®Google Scholar
• Inagaki, T., et al., 2006. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proceedings of the National Academy of Sciences of the United States of America, 103 (10), 3920–3925.
   PubMed Web of Science ®Google Scholar
• Jansen, P.L., et al., 2017. The ascending pathophysiology of cholestatic liver disease. Hepatology (Baltimore, Md.), 65 (2), 722–738.
   PubMed Web of Science ®Google Scholar
• Jin, J., et al., 2015. Activation of the farnesoid X receptor attenuates triptolide-induced liver toxicity. Phytomedicine: international journal of phytotherapy and phytopharmacology, 22 (10), 894–901.
   PubMed Web of Science ®Google Scholar
• Jonker, J.W., Liddle, C., and Downes, M., 2012. FXR and PXR: potential therapeutic targets in cholestasis. The journal of steroid biochemistry and molecular biology, 130 (3–5), 147–158.
   PubMed Web of Science ®Google Scholar
• Joyce, S.A. and Gahan, C.G., 2017. Disease-associated changes in bile acid profiles and links to altered gut microbiota. Digestive diseases (Basel, Switzerland), 35 (3), 169–177.
   PubMed Web of Science ®Google Scholar
• Katarey, D. and Verma, S., 2016. Drug-induced liver injury. Clinical medicine (London, England), 16 (Suppl 6), s104–s109.
   PubMedGoogle Scholar
• Keitel, V., Dröge, C., and Häussinger, D., 2019. Targeting FXR in cholestasis. Handbook of experimental pharmacology, 256, 299–324.
   PubMedGoogle Scholar
• Kwak, B.J., et al., 2019. The role of Phospho-c-Jun N-Terminal kinase expression on hepatocyte necrosis and autophagy in the cholestatic liver. The journal of surgical research, 241, 254–263.
   PubMed Web of Science ®Google Scholar
• Li, M., Cai, S.Y., and Boyer, J.L., 2017. Mechanisms of bile acid mediated inflammation in the liver. Molecular aspects of medicine, 56, 45–53.
   PubMed Web of Science ®Google Scholar
• Li, T., Jahan, A., and Chiang, J.Y., 2006. Bile acids and cytokines inhibit the human cholesterol 7 alpha-hydroxylase gene via the JNK/c-jun pathway in human liver cells. Hepatology (Baltimore, Md.), 43 (6), 1202–1210.
   PubMed Web of Science ®Google Scholar
• Liu, B., et al., 2017. Glutamine attenuates obstructive cholestasis in rats via farnesoid X receptor-mediated regulation of Bsep and Mrp2. Canadian journal of physiology and pPharmacology, 95 (2), 215–223.
   PubMed Web of Science ®Google Scholar
• Liu, L.L., et al., 2019. Comparative study on dose-toxicity-effect of Tripterygium Glycosides Tablets and Tripterygium wilfordii Tablets on CIA model rats. Zhongguo Zhong Yao Za Zhi, 44, 3502–3511.
   PubMedGoogle Scholar
• Li, T., et al., 2020. Picroside II protects against cholestatic liver injury possibly through activation of farnesoid X receptor. Phytomedicine: international journal of phytotherapy and phytopharmacology, 68, 153153.
   PubMed Web of Science ®Google Scholar
• Manieri, E., et al., 2020. JNK-mediated disruption of bile acid homeostasis promotes intrahepatic cholangiocarcinoma. Proceedings of the national academy of sciences of the United States of America, 117 (28), 16492–16499.
   PubMed Web of Science ®Google Scholar
• Qu, L., 2015. Study on the pharmacodynamics and toxicity of triptolide and tripterygium glycosides tablets based on sphingolipid metabolomics. PhD. Peking Union Medical College.
   Google Scholar
• Rader, D.J., 2007. Liver X receptor and farnesoid X receptor as therapeutic targets. American journal of cardiology, 100 (11 A), n15–n19.
   PubMed Web of Science ®Google Scholar
• Ru, Y., et al., 2019. Adverse events associated with treatment of Tripterygium wilfordii Hook F: a quantitative evidence synthesis. Frontiers in pharmacology, 10, 1250.
   PubMed Web of Science ®Google Scholar
• Takahashi, S., et al., 2017. Editor's highlight: farnesoid X receptor protects against low-dose carbon tetrachloride-induced liver injury through the taurocholate-JNK pathway. Toxicological sciences : an official journal of the society of toxicology, 158 (2), 334–346.
   PubMed Web of Science ®Google Scholar
• Thomas, C., et al., 2008. Targeting bile-acid signalling for metabolic diseases. Nature reviews. Drug discovery, 7 (8), 678–693.
   PubMed Web of Science ®Google Scholar
• Tian, Y.G., et al., 2019. Overview of hepatotoxicity studies on Tripterygium wilfordii in recent 20 years. Zhongguo Zhong Yao Za Zhi, 44, 3399–3405.
   PubMedGoogle Scholar
• Trauner, M. and Boyer, J.L., 2003. Bile salt transporters: molecular characterization, function, and regulation. Physiological reviews, 83 (2), 633–671.
   PubMed Web of Science ®Google Scholar
• Wang, H., et al., 2018. Regulation of mammalian UDP-glucuronosyltransferases. Current drug metabolism, 19 (6), 490–501.
   PubMed Web of Science ®Google Scholar
• Wang, Y.D., et al., 2015. Farnesoid X receptor antagonizes JNK signaling pathway in liver carcinogenesis by activating SOD3. Molecular endocrinology (Baltimore, Md.), 29 (2), 322–331.
   PubMedGoogle Scholar
• Wang, N.N., Wang, A.W., and Li, X.Y., 2012. Comparative study on rat acute toxicity of three Tripterygium wilfordii preparations. Chinese journal of pharmacovigilance, 9, 453–456.
   Google Scholar
• Wang, Y.D., et al., 2019a. [Research progress on chemical constituents and quality control of Tripterygium wilfordii preparations]. Zhongguo Zhong Yao za Zhi = Zhongguo Zhongyao Zazhi = China journal of Chinese materia medica, 44 (16), 3368–3373.
   PubMedGoogle Scholar
• Wang, Y.K., et al., 2019b. A metabolomic perspective of pazopanib-induced acute hepatotoxicity in mice. Xenobiotica; the fate of foreign compounds in biological systems, 49 (6), 655–670.
   PubMed Web of Science ®Google Scholar
• Wei, X., et al., 2021. Dehydrodiconiferyl alcohol, a lignan from Herpetospermum pedunculosum, alleviates cholestasis by activating pathways associated with the farnesoid X receptor. Phytomedicine: international journal of phytotherapy and phytopharmacology, 80, 153378.
   PubMed Web of Science ®Google Scholar
• Xiao, Y., et al., 2020. Metabolic profiling of coumarins by the combination of UPLC-MS-based metabolomics and multiple mass defect filter. Xenobiotica; the fate of foreign compounds in biological systems, 50 (9), 1076–1089.
   PubMed Web of Science ®Google Scholar
• Xiong, X., et al., 2017. Obeticholic acid protects mice against lipopolysaccharide-induced liver injury and inflammation. Biomedicine & pharmacotherapy, 96, 1292–1298.
   PubMed Web of Science ®Google Scholar
• Xu, Y., et al., 2016. Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice. Hepatology (Baltimore, MD), 64 (4), 1072–1085.
   PubMed Web of Science ®Google Scholar
• Yan, F.J., et al., 2020. C-Jun/C7ORF41/NF-κB axis mediates hepatic inflammation and lipid accumulation in NAFLD. The biochemical journal, 477 (3), 691–708.
   PubMed Web of Science ®Google Scholar
• Yang, X.N., et al., 2018b. PPARα mediates the hepatoprotective effects of nutmeg. Journal of proteome research, 17 (5), 1887–1897.
   PubMed Web of Science ®Google Scholar
• Yang, J., et al., 2017. Activation of Sirt1/FXR signaling pathway attenuates triptolide-induced hepatotoxicity in rats. Frontiers in pharmacology, 8, 260.
   PubMed Web of Science ®Google Scholar
• Yang, F., et al., 2018a. Effects of corilagin on alleviating cholestasis via farnesoid X receptor-associated pathways in vitro and in vivo. British journal of pharmacology, 175 (5), 810–829.
   PubMed Web of Science ®Google Scholar
• Yu, C., et al., 2005. Independent repression of bile acid synthesis and activation of c-Jun N-terminal kinase (JNK) by activated hepatocyte fibroblast growth factor receptor 4 (FGFR4) and bile acids. The journal of biological chemistry, 280 (18), 17707–17714.
   PubMed Web of Science ®Google Scholar
• Zhang, W., Li, F., and Gao, W., 2017. Tripterygium wilfordii inhibiting angiogenesis for rheumatoid arthritis treatment. Journal of the national medical association, 109 (2), 142–148.
   PubMed Web of Science ®Google Scholar
• Zhang, D., et al., 2019. Identification of the chemical components and metabolites of Tripterygium glycoside tablets in mice by HPLC-Q/TOF MS. Journal of chromatography. B, analytical technologies in the biomedical and life sciences, 1125, 121721.
   PubMed Web of Science ®Google Scholar
• Zhang, G., et al., 2020. Hesperidin alleviates cholestasis via activation of the farnesoid X receptor in vitro and in vivo. European journal of pharmacology, 885, 173498.
   PubMed Web of Science ®Google Scholar
• Zhao, Q., et al., 2018. Metabolic map of osthole and its effect on lipids. Xenobiotica; the fate of foreign compounds in biological systems, 48 (3), 285–299.
   PubMed Web of Science ®Google Scholar
• Zhao, Q., et al., 2017. PPARα activation protects against cholestatic liver injury. Scientific reports, 7 (1), 9967.
   PubMed Web of Science ®Google Scholar
• Zhao, Q., et al., 2019. Impaired clearance of sunitinib leads to metabolic disorders and hepatotoxicity. British journal of pharmacology, 176 (13), 2162–2178.
   PubMed Web of Science ®Google Scholar